AlydiaHealth_logo v2.png

3475 Edison Way, Suite J
Menlo Park, CA 94025 USA

CAUTION: Investigational Device. Limited by U.S. law to investigational use.

©2018 by Alydia Health.

Learn about the PEARLE Study

One complication is abnormal bleeding following delivery, also known as postpartum hemorrhage (PPH). PPH can be stopped with medication or massage of the uterus, but sometimes more invasive measures are required. This hospital is part of a clinical study of a new approach that may help avoid surgery or more invasive measures.

 

This new tool, the Jada™ System for postpartum hemorrhage control, is an investigational device that may be able to control abnormal bleeding faster than other currently available devices that are sometimes used when medication or massage does not work. If you plan to deliver at this hospital, you can be evaluated before your delivery to find out if you are eligible to participate. Most women will not have abnormal bleeding after childbirth, but since it’s impossible to know until after the delivery, all expecting mothers may be approached about the study.

The Alydia Health Team

Cindy_Domecus.jpg

Chief Regulatory Advisor

Clinical Research Manager

VP Clinical Operations

VP Quality Assurance

Clinical Research Associate

Business Development

VP Marketing

Jan Segnitz, MD

Medical Advisor

Clinical Research Coordinator

Lead Engineer

Office Manager

Jim Verhulst

Document Control

Board of Directors and Advisors

Curt LaBelle, MD, MBA

Director

Managing Partner, Global Health Investment Fund

Anne Morrissey

Director

CEO, Alydia Health

Director

President & COO,

Insulet Corp

Shacey Petrovic

Director

Fogarty Institute for Innovation, Vice Chairman of the Board

Fred St. Goar, MD

Director

Life Science Consultant and Venture Partner, Wildcat Venture Partners

Phyllis Whiteley, PhD

Strategic Advisor

CEO, Silk Road Medical

Erica Rogers

Strategic Advisor

General Partner, Canaan

Wende Hutton

The Founding Team

Jessie Becker

Co-Founder

Nathan Bair

Co-Founder